How I treat early-relapsing follicular lymphoma

Slides:



Advertisements
Similar presentations
Follicular Lymphoma Transformed Lymphoma Diffuse Large B-Cell Lymphoma
Advertisements

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications by Elias Campo, Steven H. Swerdlow, Nancy L.
Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas by Amrita Krishnan, Arturo Molina, John Zaia, David.
by Rahul Matnani, and Karthik A. Ganapathi
CD47 expression for in situ and invasive cutaneous epithelial lesions
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma.
The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma by Jonathan.
Minimal Residual Disease Measurement By Deep Sequencing Reflects Changes In Disease Load During Therapy In Diffuse Large B Cell Lymphoma Patients by Nina.
by James O. Armitage, and Dan L. Longo
Hepatitis C in the rituximab era
A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.
by Thomas S. Uldrick, and Richard F. Little
Rituximab plus CHOP (R-CHOP) overcomes bcl-2—associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)‏ by Nicolas.
Nonmyeloablative conditioning for relapsed follicular lymphoma
Superior Survival after Autologous vs
Expression of the chemokine receptors CXCR4, CXCR5, and CCR7 in primary central nervous system lymphoma by Kristoph Jahnke, Sarah E. Coupland, Il-Kang.
Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection by Koen Van Besien, Sonali Smith,
Overexpression of ornithine decarboxylase enhances endothelial proliferation by suppressing endostatin expression by Takahiro Nemoto, Hisae Hori, Masataka.
How I treat extramedullary acute myeloid leukemia
Autologous Transplantation Therapy for Chronic Myelogenous Leukemia
Late Relapses following High-Dose Autologous Stem Cell Transplantation (HD-ASCT) for Hodgkin’s Lymphoma (HL) in the ABVD Therapeutic Era  Sarah F. Keller,
The importance of lymph node examination: Simultaneous diagnosis of hypopigmented mycosis fungoides and follicular B-cell lymphoma  Mathew X. Joseph,
Runx1 deficiency predisposes mice to T-lymphoblastic lymphoma
High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin.
A distinctive subtype of t(14;18)-negative nodal follicular non-Hodgkin lymphoma characterized by a predominantly diffuse growth pattern and deletions.
by Jayesh Mehta Blood Volume 112(2): July 15, 2008
by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle
Evaluation Of Myeloablative Therapy Followed By Autologous Stem Cell Transplantation In First Remission In Patients With Advanced Stage Follicular Lymphoma.
Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma.
Primary CNS Lymphoma—Radiation-Free Salvage Therapy by Second Autologous Stem Cell Transplantation  Benjamin Kasenda, M.D., Elisabeth Schorb, M.D., Kristina.
Differential gene expression of central nervous system lymphoma
by George Z. Rassidakis, Mauricio P. Oyarzo, and L. Jeffrey Medeiros
Volume 4, Issue 5, Pages (June 2018)
Successful treatment of posttransplantation lymphoproliferative disorder (PTLD) following renal allografting is associated with sustained CD8+ T-cell restoration.
A 15-Year Analysis of Early and Late Autologous Hematopoietic Stem Cell Transplant in Relapsed, Aggressive, Transformed, and Nontransformed Follicular.
Quantifying Benefit of Autologous Transplantation for Relapsed Follicular Lymphoma Patients via Instrumental Variable Analysis  Danielle H. Oh, Haocheng.
Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma by Paul M. Barr, Thomas P. Miller, Jonathan W. Friedberg,
Impact of Conditioning Regimen on Outcomes for Patients with Lymphoma Undergoing High-Dose Therapy with Autologous Hematopoietic Cell Transplantation 
The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Follicular Lymphoma: An Evidence-Based Review  Denise M.
Cytokine Expression Pattern in Bone Marrow Microenvironment after Allogeneic Stem Cell Transplantation in Primary Myelofibrosis  Kais Hussein, Angelika.
Patient-derived xenografts of low-grade B-cell lymphomas demonstrate roles of the tumor microenvironment by W. Richard Burack, Janice M. Spence, John P.
Early Toxicities Associated with Radiation Based Conditioning for Relapsed/Refractory Hodgkin Lymphoma Patients Undergoing High Dose Therapy and Autologous.
High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Elderly Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma: A Nationwide.
Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation  Laurie H. Sehn, Timothy S. Fenske, Ginna G. Laport 
Volume 1, Issue 2, Pages (March 2015)
The International Prognostic Index Assessed at Relapse Predicts Outcomes of Autologous Transplantation for Diffuse Large-Cell Non-Hodgkin’s Lymphoma in.
Phase II Trial of 131-Iodine Tositumomab with High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed Diffuse Large B Cell Lymphoma 
Elizabeth B. Gottlin, PhD, Rex C. Bentley, MD, Michael J
Sarah A. Holstein, Paul G. Richardson, Jacob P. Laubach, Philip L
Kamal Kant Singh Abbi, Junting Zheng, Sean M
Toxicities and Outcomes for Patients with CNS Lymphoma (CNSL) Consolidated with High-Dose Therapy and Autologous Stem Cell Transplantation (HDT-ASCT)
Bridge to transplant following Bv+Bs regimen.
Yuri Fedoriw, T. Danielle Samulski, Allison M. Deal, Cherie H
Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives  Brenda M. Sandmaier, Stephen Mackinnon, Richard.
Clinical Outcome following Autologous and Allogeneic Blood and Marrow Transplantation for Relapsed Diffuse Large-Cell Non-Hodgkin’s Lymphoma  Ivan Aksentijevich,
Histopathology and bcl-2 immunohistochemistry of in situ follicular lymphoma.(A-B) Low-power view of H&E-stained (A) and bcl-2–stained (B) sections showing.
by Matthew S. Painschab, Kate D
Quiz Page January 2010 American Journal of Kidney Diseases
How I treat Burkitt lymphoma in adults
Resistance mechanism for ibrutinib in marginal zone lymphoma
Biology and treatment of Richter syndrome
An algorithmic approach to FL
Fig. 3. A photomicrograph shows the combination of the numerous, inter-anastomosing vascular spaces and more solid, spindle-cell areas effacing the normal.
Polatuzumab Vedotin Combined with Bendamustine (B) and Rituximab (R) or Obinutuzumab (G) in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma.
Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?
by Lapo Alinari, and Kristie A. Blum
by Victor A. Chow, Mazyar Shadman, and Ajay K. Gopal
Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy.
Optimizing therapy for nodal marginal zone lymphoma
Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and.
Presentation transcript:

How I treat early-relapsing follicular lymphoma by Carla Casulo, and Paul M. Barr Blood Volume 133(14):1540-1547 April 4, 2019 ©2019 by American Society of Hematology

Typical immunohistochemistry of follicular lymphoma. Typical immunohistochemistry of follicular lymphoma. (A) Predominance of small centrocytes in follicular lymphoma (hematoxylin and eosin; original magnification ×400). (B) BCL2 expression in follicular lymphoma (immunohistochemical stain for BCL2; original magnification ×40). (C) Nodal architecture is effaced by follicular lymphoma (hematoxylin and eosin; original magnification ×12.5). Images supplied by Richard Burack, Wilmot Cancer Institute. Carla Casulo, and Paul M. Barr Blood 2019;133:1540-1547 ©2019 by American Society of Hematology

Our approach to treating patients with FL and early relapse. Our approach to treating patients with FL and early relapse. ASCT, autologous stem cell transplantation; DLBCL, diffuse large B-cell lymphoma; HDT, high-dose therapy; R/R, relapsed/refractory. Carla Casulo, and Paul M. Barr Blood 2019;133:1540-1547 ©2019 by American Society of Hematology

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com Inc. All rights reserved.